Tropisetron long-acting slow-release transdermal patch and preparation method thereof

By designing a three-layer structure totansetron long-acting sustained-release transdermal patch, the pain and gastrointestinal reaction problems in totansetron administration are solved, and the long-acting sustained-release and stable absorption of the drug is achieved. Improves bioavailability and safety, suitable for chemotherapy and antiemetic treatment in postoperative patients.

CN119074698APending Publication Date: 2024-12-06YANTAI UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411198831.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-29
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing tornasetron administration method has problems such as pain, gastrointestinal adverse reactions and oral difficulties caused by intravenous administration, and the traditional administration method is inconvenient, especially in patients after chemotherapy and postoperative patients, it is difficult to maintain a constant antiemetic effect. , and there are side effects.

Method used

The long-acting sustained release transdermal patch with a three-layer structure is composed of totansetron free alkali, pressure sensitive glue, penetration enhancer and tackifier, and passes through the backing layer and the drug-containing layer and protective layer design to achieve sustained release and stable absorption of drugs.

Benefits of technology

Effectively avoid adverse gastrointestinal reactions, achieve long-term sustained release of totanetron, improve bioavailability and safety, enhance patient's medication compliance and convenience, reduce the pain of nausea and vomiting, and is applicable in chemotherapy and postoperative patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005017294180000021
    Figure BDA0005017294180000021
  • Figure BDA0005017294180000051
    Figure BDA0005017294180000051
  • Figure BDA0005017294180000071
    Figure BDA0005017294180000071
Patent Text Reader

Abstract

The invention relates to a tropisetron long-acting slow-release transdermal patch and a preparation method thereof. The tropisetron long-acting slow-release transdermal patch is composed of three layers which are a backing layer, a drug-containing matrix layer and a protective layer in sequence, and the drug-containing layer is composed of tropisetron free alkali or pharmaceutically acceptable salt thereof, a pressure-sensitive adhesive, a penetration enhancer and a tackifier. The tropisetron long-acting sustained-release transdermal patch is prepared through dosage form improvement, gastrointestinal tract adverse reactions caused by oral administration are effectively avoided, the tropisetron long-acting sustained-release transdermal patch can be continuously applied for 3 days, long-acting sustained release of tropisetron for 3 days is achieved, and compared with a common preparation, the tropisetron long-acting sustained-release transdermal patch can effectively improve the compliance of a patient.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a transdermal patch and a preparation method thereof, in particular to a tropisetron long-acting sustained-release transdermal patch and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. Background Art

[0002] Tropisetron is a highly effective and selective competitive antagonist of 5-hydroxytryptamine 3 (5-HT3) receptors in peripheral neurons and the central nervous system. It inhibits the vomiting reflex caused by chemotherapy drugs or other emetic factors by blocking 5-HT3 receptors, thereby playing an antiemetic role. In addition, tropisetron can also help relieve abdominal distension and protect the gastric mucosa. Tropisetron is mainly used to prevent and treat nausea and vomiting caused by cancer chemotherapy, as well as nausea and vomiting after general anesthesia surgery. It is widely used in clinical practice and has significant effects. It is clearly effective for nausea and vomiting caused by moderate and severe emetogenic drugs. Compared with other 5-HT3 receptor antagonists, tropisetron hydrochloride also has the advantages of mild side effects, low incidence of drug interactions and long duration of action, so it is widely used. The traditional administration of tropisetron hydrochloride is intravenous injection on the first day and oral administration from the second to the sixth day. Intravenous administration can only take effect for a short time, and patients with cancer and undergoing surgery will experience severe pain after intravenous administration, and oral administration is difficult due to gastrointestinal dysfunction, which limits its clinical application to a certain extent. Because oral administration has gastrointestinal adverse reactions, intravenous administration has poor compliance and other problems. Intravenous administration can only be performed under medical supervision and causes patients to feel obvious discomfort, such as redness and burning at the injection site. In pediatric drugs, there are problems caused by children not liking injection needles, and it is always related to injection needle adhesion damage. Oral administration is often quite unbearable due to the use of such delivery routes in patients with severe nausea and vomiting and patients with head and neck cancer. The pulsatility of oral delivery can also cause problems caused by deviation from the therapeutic window (usually causing side effects). Rectal delivery can only prevent the pulsatility of oral delivery to a certain extent and is not the most convenient or widely accepted means of delivery. Transdermal delivery is a way of absorbing drugs through the skin. After the drug is applied to the skin, it passes through the stratum corneum, diffuses through the skin, and is absorbed by the capillaries into the systemic circulation. This method has the advantages of providing a long-lasting and constant drug release rate, reducing toxic and side effects, being easy to use, and reducing individual differences. However, information on the specific development progress, clinical trial data, and marketing status of the long-acting sustained-release transdermal patch of tropisetron may be limited due to the development stage and confidentiality requirements. Therefore, there is a need for a non-oral drug delivery system that can maintain a constant antiemetic plasma concentration for an extended period of time. Transdermal drug delivery through the skin is an approved method for maintaining a relatively steady-state plasma concentration of a therapeutic agent while preventing pain, discomfort, and the inconvenience of intravenous, oral, and rectal drug delivery. Therefore, post-chemotherapy and post-surgery transdermal antiemetic therapy has the potential to relieve the suffering of patients who not only experience nausea and vomiting caused by the original therapy, but also relieve the significant discomfort associated with the medical condition itself. Summary of the invention

[0003] In order to solve the deficiencies of the prior art, the object of the present invention is to provide a tropisetron long-acting sustained-release transdermal patch and a preparation method thereof.

[0004] In order to achieve the above object, the present invention adopts the following technical solution:

[0005] A tropisetron long-acting sustained-release transdermal patch, consisting of three layers, namely, a backing layer, a drug-containing matrix layer, and a protective layer, wherein the drug-containing layer is composed of tropisetron free base or a pharmaceutically acceptable salt thereof, a pressure-sensitive adhesive, a penetration enhancer, and a tackifier. The contents of the components of the drug-containing layer are specifically as follows, in parts by mass:

[0006]

[0007] Preferably, the backing layer is selected from one of polyethylene film, polyvinyl chloride film, polypropylene film, polyester film, aluminum foil, aluminum-coated polyester film, thermoplastic resin film and non-woven fabric.

[0008] Preferably, the protective layer is selected from one of polyethylene film, polystyrene film, polypropylene film and release paper treated with paraffin or dimethyl silicone oil release agent.

[0009] Preferably, the pharmaceutically acceptable salt of tropisetron includes: tropisetron hydrochloride and the like.

[0010] Preferably, the pressure-sensitive adhesive is any one or a combination of any two of polyvinyl alcohol, cellulose acetate, acrylate containing carboxyl groups, acrylate containing hydroxyl groups, acrylate without functional groups, polybutene, polysiloxane and natural rubber.

[0011] Preferably, the penetration enhancer is composed of one or more of levulinic acid, triacetin, and propylene glycol.

[0012] Preferably, the adhesive of the present invention is any one or a combination of any two of polybutadiene, diene isoprene styrene star polymer and poly(butyl methacrylate-methyl methacrylate) copolymer.

[0013] Other monomers are also suitable provided they have a sufficiently low glass transition temperature (Tg).

[0014] A method for preparing the aforementioned tropisetron long-acting sustained-release transdermal patch comprises the following steps:

[0015] Step 1: Place the pressure-sensitive adhesive and the adhesive in the same container, add the solvent, and shake to evenly disperse the adhesive in the base pressure-sensitive adhesive;

[0016] Step 2: adding tropisetron free base or a pharmaceutically acceptable salt thereof and a penetration enhancer into a solvent and dissolving them into a clear solution;

[0017] Step 3: Transfer all the obtained clear solution to the dispersed matrix, keep shaking after protecting from light, stir evenly and let stand to obtain the drug-loaded matrix;

[0018] Step 4: coating the obtained drug-loaded matrix on the protective layer to obtain a drug-containing layer, and then drying it in an oven at 60°C for a period of time and then naturally cooling it to room temperature;

[0019] Step 5: Cover the drug-containing layer with a backing layer, and cut the layer into pieces to obtain the tropisetron transdermal patch.

[0020] Preferably, in step 1 and step 2, the solvent is any one or a combination of any two of ethyl acetate, n-heptane and anhydrous ethanol.

[0021] Preferably, in step 4, the coating thickness of the drug-loaded matrix is ​​controlled to be 0.30±0.01 mm.

[0022] The present invention is beneficial in that:

[0023] (1) The present invention prepares a long-acting sustained-release transdermal patch of tropisetron by improving the dosage form, which effectively avoids gastrointestinal adverse reactions caused by oral administration and can be applied continuously for 3 days, thus achieving a long-acting sustained-release of tropisetron for 3 days. Compared with general preparations (such as capsules, injections, orally disintegrating tablets), it can effectively improve patient compliance;

[0024] (2) The present invention improves the dosage form to achieve direct entry of tropisetron from the patch through the skin into the body circulation, avoiding the first-pass effect of the liver, improving the bioavailability of tropisetron, reducing its dosage, and effectively ensuring its effectiveness and safety;

[0025] (3) The long-acting sustained-release transdermal patch of tropisetron prepared by the present invention has good safety and a continuous and stable transdermal effect, which greatly improves the medication compliance and convenience of patients.

[0026] Therefore, with the development of drug delivery systems and material science, the long-acting sustained-release transdermal patch of tropisetron is expected to become an important choice for patients undergoing cancer chemotherapy and other antiemetic treatments in the future. This patch will further improve the quality of life of patients, reduce the medical burden, and provide more possibilities for personalized treatment and drug safety. DETAILED DESCRIPTION

[0027] The present invention is described in detail below with reference to specific embodiments.

[0028] 1. Analysis of the physical and chemical properties of tropisetron hydrochloride

[0029] The chemical name of Tropisetron Hydrochloride (TRO) is: 3-indolecarboxylic acid (8-methyl-8-azabicyclo[3.2.1]-3α-octyl) ester hydrochloride. TRO is the only 3 5-HT with the same main ring structure 3 Receptor antagonist, long-lasting effect, similar to 5-HT 3 The receptor binding capacity is 13,000 times higher than other receptors. It acts as a 5-HT receptor in peripheral neurons and the central nervous system. 3 It is a highly effective and selective antagonist of the receptor, mainly used to prevent and treat CINV. It is effective for nausea and vomiting caused by moderate to severe emetogenic drugs, with complete control rates of 75% and 47% to 73%, respectively.

[0030] 2. Preparation of Tropisetron Transdermal Patch

[0031] The tropisetron transdermal patch provided by the present invention is composed of three layers, namely: a backing layer, a drug-containing layer, and a protective layer, wherein:

[0032] Backing layer: one of polyethylene film, polyvinyl chloride film, polypropylene film, polyester film, aluminum foil, aluminum-coated polyester film, thermoplastic resin film and non-woven fabric is selected to protect the drug-containing layer from environmental influences;

[0033] Drug-containing layer: i.e., active layer, the active ingredient is tropisetron free base or its pharmaceutically acceptable salt;

[0034] Protective layer: Choose one of the polyethylene film, polystyrene film, polypropylene film and anti-sticking paper treated with paraffin or dimethyl silicone oil release agent, which needs to be removed before use.

[0035] First, the composition of the drug-containing layer is introduced in detail.

[0036] The drug-containing layer contains, in addition to tropisetron free base or a pharmaceutically acceptable salt thereof, a pressure-sensitive adhesive, an adhesive and a penetration enhancer. The mass fractions of each component are shown in Table 1:

[0037] Table 1 Composition and content of drug-containing layer

[0038] Composition Mass fraction Tropisetron free base or a pharmaceutically acceptable salt thereof 25 servings Pressure sensitive adhesive 200 copies Adhesives 50 servings Penetration enhancers 1 serving

[0039] in:

[0040] The pressure-sensitive adhesive is selected from any one or any combination of polyvinyl alcohol, cellulose acetate, acrylate containing carboxyl groups, acrylate containing hydroxyl groups, acrylate without functional groups, polybutene, polysiloxane and natural rubber;

[0041] The adhesive is selected from any one or any combination of polybutadiene, diene isoprene styrene star polymer and poly (butyl methacrylate-methyl methacrylate) copolymer;

[0042] The penetration enhancer is selected from one or more of levulinic acid, triacetin, and propylene glycol.

[0043] Next, the preparation method of the entire transdermal patch is introduced in detail.

[0044] 1. Prepare materials

[0045] The specific materials selected for the backing layer, the drug-containing layer (including active ingredients, pressure-sensitive adhesive, adhesive and penetration enhancer) and the protective layer are shown in Table 2.

[0046] Table 2 Specific materials selected for backing layer, drug-containing layer and protective layer

[0047]

[0048] First, prepare the materials required for each layer according to Table 2, and then accurately weigh the components of the drug-containing layer according to the formula in Table 1. In this specific embodiment, 1 mass part = 0.02 g. Specifically, accurately weigh 0.5 g of tropisetron free base or a pharmaceutically acceptable salt thereof, 4.0 g of pressure-sensitive adhesive, 1.0 g of adhesive and 0.02 g of penetration enhancer.

[0049] In each specific embodiment:

[0050] (1) Acrylates (pressure-sensitive adhesives) containing hydroxyl groups are specifically used 387-2510;

[0051] (2) Acrylates (pressure-sensitive adhesives) containing carboxyl groups are specifically used 387-2054;

[0052] (3) Acrylates (pressure-sensitive adhesives) without functional groups are specifically used 87-4098;

[0053] (4) Star-shaped polyisoprene (adhesive) is specifically C-(IR) n ;

[0054] (5) Poly(butyl methacrylate-methyl methacrylate) copolymer (adhesive) is specifically used. B;

[0055] (6) Polybutadiene (adhesive) Specifically used is C-(BR) n .

[0056] 2. Preparation of drug-loaded matrix

[0057] First, place the weighed pressure-sensitive adhesive and adhesive in a 20 ml glass liquid scintillation bottle, add 1 ml of ethyl acetate (solvent, which can be replaced by n-heptane or anhydrous ethanol) into the glass liquid scintillation bottle, place the glass liquid scintillation bottle on a micro stirring wheel, and shake it at a speed of 30 r / min for 24 hours to evenly disperse the adhesive in the pressure-sensitive adhesive (matrix).

[0058] Then, the weighed tropisetron free base or its pharmaceutically acceptable salt and the penetration enhancer are added into 1 ml of ethyl acetate (the solvent can be replaced by n-heptane or anhydrous ethanol) to dissolve into a clear solution.

[0059] Afterwards, the obtained clear solution was transferred to the dispersed matrix. After being protected from light, the glass liquid scintillation bottle was placed on the micro stirring wheel again and continued to shake at a speed of 30 r / min for 24 hours. After stirring evenly, it was allowed to stand for 30 minutes (purpose: to remove bubbles) to obtain the drug-loaded matrix.

[0060] 3. Coating of drug-loaded matrix

[0061] At room temperature, the coating was carried out using a coating machine at a speed of 5 mm·s -1 The drug-loaded matrix obtained above was coated on the protective layer at a speed of 0.30±0.01 mm in thickness to obtain a drug-containing layer, which was then dried in an oven at 60°C for 15 min and naturally cooled to room temperature after being taken out.

[0062] 4. Lamination and slitting

[0063] The drug-containing layer was covered with a backing layer, and then cut with a circular grinder with a diameter of 1.5 cm to obtain a tropisetron transdermal patch. The release area of ​​the drug-containing layer was 1.76 cm 2 .

[0064] The prepared tropisetron transdermal patch is placed in a sealed condition for use.

[0065] 3. In vitro skin permeation test

[0066] Test method: The modified Franz diffusion cell method was used, with the upper chamber as the diffusion chamber and the lower chamber as the receiving chamber. 2 ), remove the anti-adhesive layer, adhere to the skin of nude mice, and lay flat on the diffusion interface of Franz vertical diffusion cell, with the stratum corneum facing the diffusion chamber. The volume of the receiving cell is 12 ml, and the effective diffusion area is 1.767 cm 2, heated in a constant temperature water bath, the temperature was controlled at (32±0.5)℃, the receiving pool was filled with preheated release medium (0.01M phosphate buffer, pH 7.4), the bubbles were exhausted, the pool was equipped with an electromagnetic stirrer and rotated at 600rpm. 4.5ml of samples were taken at 3, 6, 9, 12, 18, 24h, 48h and 72h (the same amount of release medium was added at the same temperature), the receiving solution was analyzed, and the cumulative transdermal amount of the drug (Q n / μg·cm -2 ), cumulative skin penetration rate (Q n / %) and steady-state transdermal rate (J ss / μg·cm -2 ·h -1 ). Q n is the cumulative permeability per unit area at the nth time point, A is the effective permeability area, C n is the drug mass concentration measured at the nth point, V is the volume of the receiving pool, C i is the drug mass concentration measured at the (n-1)th point, V i Q is the volume of each sample. n % = Q n / W, Q / % is the cumulative permeability at the nth time point, A is the effective permeation area, and W is the actual total amount of drug per unit area.

[0067] Chromatographic conditions: Welch-C18 reverse phase column (250 mm × 4.6 mm, 5 μm), mobile phase: KH2PO4 buffer (pH 4.5) - acetonitrile (75:25), flow rate: 1 mL / min, injection volume: 20 μL, column temperature: 30 ° C, detection wavelength: 285 nm.

[0068] When the lumepirone transdermal patches prepared in Examples 1 to 6 were attached to the intact skin of nude mice, the lumepirone transdermal patches prepared in Examples 1, 2 and 3 had a higher transdermal amount, and the cumulative transdermal amount within 72 hours was larger.

[0069] Experimental Example 2 In vivo pharmacokinetics study of tropisetron transdermal patch

[0070] 2.1 Experimental Instruments

[0071] G7117B 1290 High Performance Liquid Chromatograph Agilent, USA

[0072] API 6470 Triple Quadrupole Tandem Mass Spectrometer Applied Biosystem, USA GL21M High-speed Refrigerated Centrifuge Changsha Xiangzhi Centrifuge Instrument Co., Ltd. 2.2 Materials and reagents

[0073]

[0074] 2.3 Experimental animals

[0075] New Zealand White Rabbit Shandong Luye Pharmaceutical Co., Ltd. Animal Experiment Center

[0076] 2.5 Experimental design

[0077] Twelve New Zealand white rabbits were weighed and randomly divided into an intravenous injection group (IV), a transdermal patch group, and an oral group, with 4 rabbits in each group (4±0.2kg). For the intravenous injection group, the intravenous dose of 0.275 mg kg was calculated based on the maximum daily oral dose of humans. -1 , tropisetron hydrochloride injection was administered to rabbits through the ear vein. Blood was collected from the rabbit ear vein at 0min, 5min, 10min, 20min, 30min, 1h, 2h, 4h, 6h, 8h, and 12h after administration, placed in a heparinized centrifuge tube, and immediately centrifuged at 5000rpm for 10min in a 4℃ centrifuge. The supernatant was taken and stored in a -80℃ refrigerator for testing. For the oral group, the rabbit intravenous dose was converted to 0.458mg·kg based on the maximum daily oral dose of humans. -1 . Blood was collected from the rabbit ear vein at 0.5h, 1h, 2h, 4h, 6h, 8h, and 12h after administration, placed in a heparinized centrifuge tube, and immediately centrifuged at 5000rpm for 10min in a 4℃ centrifuge. The supernatant was taken and stored in a -80℃ refrigerator for testing. In the patch group, the dosage was 20mg / patch. The New Zealand white rabbit was fixed, the hair on its back was cut carefully with ophthalmic scissors until it was close to the skin, and a small amount of depilatory cream was applied to remove the back hair, and a smooth area was formed as much as possible. Be careful not to damage the skin. Implementation Case 4 was applied to the shaved area, fixed with medical tape, and the patch was removed after 24h. Blood was collected from the rabbit ear vein at 0min, 30min, 1h, 2h, 4h, 6h, 8h, 12h, 24h, 48h, and 72h after administration, placed in a heparinized centrifuge tube, and immediately centrifuged at 5000rpm for 10min in a 4℃ centrifuge. The upper plasma was collected and stored in a -80℃ refrigerator for testing.

[0078] 2.6 LC-MS / MS method for determining drug content in rabbit blood

[0079] Chromatographic method: A ZORBAX XDB-C18 column (50 mm × 2.1 mm, 3.5 μm) was used, the mobile phase was methanol-0.1% formic acid aqueous solution (80:20), isocratic elution was 3.5 min, and the flow rate was 0.4 mL min -1 , column temperature was 40 °C, and injection volume was 5 μL.

[0080] Mass spectrometry method: Electrospray ionization source (ESI) was used, the scanning mode was multiple reaction monitoring (MRM), and the positive ion mode was used for detection. The ion spray voltage was 5500 V, the ion source temperature was 450 ° C, the curtain gas (CUR) was 10 psi, the pressure of source gas 1 (GS1) was 45 psi, and the pressure of source gas 2 (GS2) was 45 psi. The mass spectrometry parameters of tropisetron hydrochloride reference and IS are shown in Table 2.

[0081] Table 2 Mass spectrometry parameters of tropisetron hydrochloride reference substance and IS

[0082] Compound Q1Mass / Da Q3Mass / Da DP / volts EP / volts CE / volts CXP / volts Tropisetron Hydrochloride 284.9 124.1 106 10 33 8 IS 312.9 138.1 120 10 30 10

[0083] Preparation of reference solution and IS solution: Accurately weigh appropriate amounts of tropisetron hydrochloride reference and IS reference, and dissolve them in methanol to 0.2 mg / mL -1 Accurately pipette an appropriate amount of tropisetron hydrochloride stock solution, use 50% methanol aqueous solution as diluent, and dilute step by step to 1000, 400, 200, 100, 40, 20, 10, 4, and 2 ng·mL -1 A series of standard solutions were stored at -20°C for later use. Accurately pipette an appropriate amount of IS stock solution and dilute it to 500 ng·mL with 50% methanol aqueous solution. -1 The IS solution was stored at -20°C until use.

[0084] Plasma sample treatment: The sample was treated by liquid-liquid extraction. A 2 mL EP tube was added with 100 μL of plasma sample and 5 μL of IS solution, and vortexed for 30 s. 1.5 mL of ethyl acetate was added, vortexed for 10 min, and centrifuged at 13,000 rpm for 10 min. All supernatants were transferred to a 10 mL clean glass centrifuge tube and dried with nitrogen. 100 μL of 50% methanol aqueous solution was added for reconstitution, vortexed for 10 s, and the supernatant was put into a sample injection bottle.

[0085] 2.7 Determination of blood drug concentration in New Zealand white rabbits

[0086] The blood drug concentration data of the intravenous injection group, patch group and oral group of tropisetron hydrochloride showed that: the absorption and elimination of rabbits were rapid after intravenous injection and oral administration, while the absorption and elimination of transdermal patches were relatively slow, the blood drug concentration fluctuated less, and the action time was prolonged, up to 3 days, with a certain sustained-release effect.

[0087] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A tropisetron long-acting sustained-release transdermal patch, Features The tropisetron long-acting sustained-release transdermal patch is composed of three layers, namely, a backing layer, a drug-containing matrix layer, and a protective layer, wherein the drug-containing layer is composed of tropisetron free base or a pharmaceutically acceptable salt thereof, a pressure-sensitive adhesive, a penetration enhancer, and a tackifier. The contents of the components of the drug-containing layer are specifically as follows, in parts by mass: 25 parts of tropisetron free base or a pharmaceutically acceptable salt thereof, 200 copies of pressure sensitive adhesive, 1 part of penetration enhancer, Adhesive 50 parts.

2. A tropisetron long-acting sustained-release transdermal patch according to claim 1, It is characterized in that The backing layer is selected from one of polyethylene film, polyvinyl chloride film, polypropylene film, polyester film, aluminum foil, aluminum-coated polyester film, thermoplastic resin film and non-woven fabric.

3. A tropisetron long-acting sustained-release transdermal patch according to claim 1, It is characterized in that The protective layer is selected from one of polyethylene film, polystyrene film, polypropylene film and anti-sticking paper treated with paraffin or dimethyl silicone oil release agent.

4. A tropisetron long-acting sustained-release transdermal patch according to claim 1, It is characterized in that The pharmaceutically acceptable salts of tropisetron include: tropisetron hydrochloride.

5. A tropisetron long-acting sustained-release transdermal patch according to claim 1, It is characterized in that The pressure-sensitive adhesive is selected from any one or any combination of polyvinyl alcohol, cellulose acetate, acrylate containing carboxyl groups, acrylate containing hydroxyl groups, acrylate without functional groups, polybutene, polysiloxane and natural rubber.

6. A tropisetron long-acting sustained-release transdermal patch according to claim 1, It is characterized in that The penetration enhancer is composed of one or more of levulinic acid, triacetin, and propylene glycol.

7. The long-acting sustained-release transdermal patch of tropisetron according to claim 1, It is characterized in that The binder is any one of polybutadiene, diene isoprene styrene star polymer and poly copolymer or a combination of any two of them.

8. A method for preparing the long-acting sustained-release transdermal patch of tropisetron according to claim 1, Features The following steps are involved: Step 1: Place the pressure-sensitive adhesive and the adhesive in the same container, add the solvent, and shake to evenly disperse the adhesive in the base pressure-sensitive adhesive; Step 2: adding tropisetron free base or a pharmaceutically acceptable salt thereof and a penetration enhancer into a solvent and dissolving them into a clear solution; Step 3: Transfer all the obtained clear solution to the dispersed matrix, keep shaking after protecting from light, stir evenly and let stand to obtain the drug-loaded matrix; Step 4: coating the obtained drug-loaded matrix on the protective layer to obtain a drug-containing layer, and then drying it in an oven at 60°C for a period of time and then naturally cooling it to room temperature; Step 5: Cover the drug-containing layer with a backing layer, and cut the layer into pieces to obtain the tropisetron transdermal patch.

9. The method for preparing the tropisetron long-acting sustained-release transdermal patch according to claim 8, It is characterized in that In step 1 and step 2, the solvent is any one of ethyl acetate, n-heptane and anhydrous ethanol or a combination of any two thereof.

10. The method for preparing the tropisetron long-acting sustained-release transdermal patch according to claim 8, It is characterized in that In step 4, the coating thickness of the drug-loaded matrix is ​​controlled to be 0.30±0.01 mm.